A study run by the US National Institutes of Health (NIH) has suggested that people who were given Johnson & Johnson Inc's (NYSE:JNJ) COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer Inc (NYSE:PFE)/BioNTech SE (Nasdaq:BNTX) or Moderna Inc (Nasdaq:MRNA), Reuters news agency reported on Thursday.
This preliminary study, which hasn't yet been peer reviewed, included over 450 adults who received initial shots from Pfizer, Moderna or Johnson & Johnson and showed that "mixing and matching" booster shots of different types is safe in adults.
Moderna's and Pfizer's vaccines are based on messenger RNA while J&J's uses viral vector technology.
The NIH study also contrasted the safety and immune response of volunteers who were boosted with the same type of shot they had been given for their initial vaccination with those who received a different type of shot as a booster.
Findings showed that mixing and matching doses for a booster produced similar side effects to those seen in primary vaccinations and raised no significant safety concerns.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma